Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen, Inc. announced a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding for the exclusive rights to develop and commercialize OCU400, a modifier gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa. The deal includes up to $4 million in upfront and near-term development payments, potential $255 …